Parkin disease: a clinicopathologic entity? - Wikidata - wikimedia - TriplyDB

Parkin disease: a clinicopathologic entity?

Parkin disease: a clinicopathologic entity?

http://www.wikidata.org/entity/Q30594306

about

TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy The Monoamine Brainstem Reticular Formation as a Paradigm for Re-Defining Various Phenotypes of Parkinson's Disease Owing Genetic and Anatomical Specificity.Olfaction in Parkin carriers in Chinese patients with Parkinson disease The pallidopyramidal syndromes: nosology, aetiology and pathogenesis.The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase Parkin A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson's disease.Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies.A mitocentric view of Parkinson's disease.Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement.α-Synuclein and Parkinsonism: Updates and Future Perspectives.Integrating Patient Concerns into Parkinson's Disease Management.Selective neuronal vulnerability in Parkinson disease.Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.The synaptic function of parkin.Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients.Phenotypic Discordance in Siblings with Identical Compound Heterozygous PARK2 Mutations Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Parkinson's disease - the story of an eponym.A Focus on the Beneficial Effects of Alpha Synuclein and a Re-appraisal of Synucleinopathies.Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.Prying into the Prion Hypothesis for Parkinson's Disease.Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.Cardiac 123I-MIBG scintigraphy: A window into the brain in Parkinsonism?A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in

P2860

Q26851112-82C8BA6F-539A-4074-BAD5-C8087EEA2A33 Q28077356-8991E241-E04D-4932-8B42-142FAFB31084 Q29147504-D8D6FA52-15DE-45C4-A1EE-970926C2D659 Q30357944-4692B0E5-4583-428F-AA63-B5A35CC7F1A4 Q33695309-CDBBA328-2CF8-408A-BA3B-B3ED9EDE48DF Q34336776-819587BF-69C6-4070-AD91-DCE8DDAD8B83 Q35054613-CDDEDB88-A1B7-4463-9539-88DEFC57A26A Q35442728-4CD062F5-3CC1-4C90-A104-C5069BF31150 Q35769443-1C8C1B39-8B42-4468-9ED9-07F5167E80C3 Q35888058-47B45117-71A6-4D1D-ABAF-EB3B0A6CB694 Q35924508-ED528267-FB25-46A7-9387-485173DFE5F8 Q35996880-DE2457AB-F4C7-4EFA-9597-86161EC0AFB0 Q36373170-BEC7D2CC-DBF2-41A8-96CC-8DBB22C4472F Q37692348-FDBCADAB-AED8-45CC-8C18-3991802D4C40 Q38107478-4CF537CC-E238-43B3-9E19-23444BE6F824 Q38211382-43FBDEC8-6D53-4ADB-878E-C7053532E214 Q38258228-2F73B051-D333-4267-97BE-68D853953C7B Q38742153-8BAC69B5-8E8D-4C95-A6D0-85C7E79E0CD7 Q39094808-A65D7BC3-B742-4D6B-A863-EFC3BC428796 Q39095738-CDB794C4-4D4D-4A6C-88DB-4E16235FEA9A Q39119095-E260FDDA-AFD0-4786-95DA-BE77B32C02D8 Q39196417-3F0A2489-F6DE-40CE-965D-C041973727AA Q40860918-5E6E37E8-4F49-4E9C-8712-DCF2222925C4 Q41082517-0A55AA60-0353-4CC3-B291-6A9B9F091F4A Q42338923-D1DA6A43-3315-4419-87D9-FB697E33FE56 Q46354756-80895A3D-BEEC-4920-B124-CAB2DBE857EB Q47198056-4AE52308-9D46-4C9A-A705-6AB6292B8608 Q47389795-DB28D58F-3132-4F22-BD47-F7428042F605 Q47619453-83541485-A66A-4563-870A-2E8E1015FB58 Q47665674-26CC61B7-9B86-466B-B366-79198211544D Q48280181-35C2EEFB-4D61-4538-BADB-8CF522BE1DD8 Q52145267-17168CEF-68E2-4D12-8501-FA851CA74328 Q57646317-B638A765-6013-4250-8F19-09DF175A03CC

P2860

Parkin disease: a clinicopathologic entity?

http://www.wikidata.org/entity/Q30594306

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Parkin disease: a clinicopathologic entity?

@ast

Parkin disease: a clinicopathologic entity?

@en

type

label

Parkin disease: a clinicopathologic entity?

@ast

Parkin disease: a clinicopathologic entity?

@en

prefLabel

Parkin disease: a clinicopathologic entity?

@ast

Parkin disease: a clinicopathologic entity?

@en

P1433

Q30594306-8FFFE8DE-E9F0-44D6-A9F0-88FBE1873A1D

P1476

Q30594306-6D7C0ECE-49CD-4AFD-A869-8BC28EFC46D9

P2093

Q30594306-0B9730AB-D283-4B49-A18E-3E4CB008576F

Q30594306-24050699-1B38-4785-9CFD-AE0B26F53202

Q30594306-46430FEA-1346-40A5-A23D-E81C260F979C

Q30594306-4873F0E1-DA7F-4F7B-AE80-47F3A3172F6B

Q30594306-4A0044A6-F55D-4115-8841-7A2318E02C8C

Q30594306-56C820CC-6F6E-4824-90AF-FB4F7F9CA066

Q30594306-8A4B8E0C-D4A8-4C7D-879C-C3596F7853C8

Q30594306-B0540951-F82B-4968-A98D-4D06EB388721

Q30594306-CA60C8C2-DCE6-4A9F-874E-E868E6B08A8B

Q30594306-DA670449-AFF1-46F8-8D1A-7A540504A8F8

P2860

Q30594306-033FB54D-35D7-421D-A8A8-DA2DBC0FC83F

Q30594306-085D372E-A6BF-4BB3-8BC9-424230BF0C0F

Q30594306-170E8B84-5412-459B-9D23-72819AFEB007

Q30594306-17D82A7E-1128-41AD-AB32-AC5E3F707831

Q30594306-1D2E6249-0ADB-4CB8-9424-06169865DEB6

Q30594306-268148F7-293A-4E66-9474-7684C5087BBD

Q30594306-3268E192-CBED-4B6E-A701-5D58289D6BA8

Q30594306-354B6395-3D28-4DF1-8AF0-CC8F9BD99808

Q30594306-367BA899-56EE-4933-AF72-5D7755D11B2F

Q30594306-3B5CD342-29B8-4EAE-8E2C-FC6F61045954

P304

Q30594306-EC4AA209-9979-40E0-8FF2-854480824519

P31

Q30594306-15A412F6-64A0-4D26-9B89-9B14F3498A73

P356

Q30594306-AFABD4E2-3DEB-4420-B246-A4D3FC007BC8

P407

Q30594306-11469ECC-F4AD-4004-B3EB-45C4D4560496

P433

Q30594306-725F00F4-332D-474F-969D-58034F46723F

P478

Q30594306-75F14DEF-7A54-4638-B28B-F32BBEF21DAB

P50

Q30594306-12CB601A-0108-4648-A87E-E0E9DB39CB61

Q30594306-8A843228-12BC-4295-9F96-96E93C03C572

Q30594306-9302BCF5-4C0E-478C-A5FE-6808419EC513

Q30594306-E4821853-EF2B-414E-A72F-E1AB97BFBE71

P577

Q30594306-4C127114-8803-4565-BFDB-A5C4D456EE9C

P5875

Q30594306-49040479-4BC5-4955-9B31-1B3BDD3917B2

P698

Q30594306-45ED0DD8-B4B7-495C-A851-097F74DD22E4

P932

Q30594306-2B35AFFD-59C0-4B35-9F83-F6EC074FB6F8

P356

JAMANEUROL.2013.172

P1433

P1476

Parkin disease: a clinicopathologic entity?

@en

P2093

Daniel G Healy

http://www.w3.org/2001/XMLSchema#string

Francesca M Brett

http://www.w3.org/2001/XMLSchema#string

Janice L Holton

http://www.w3.org/2001/XMLSchema#string

Karen M Doherty

http://www.w3.org/2001/XMLSchema#string

Laura Parkkinen

http://www.w3.org/2001/XMLSchema#string

Michael Farrell

http://www.w3.org/2001/XMLSchema#string

Niccolo E Mencacci

http://www.w3.org/2001/XMLSchema#string

Tamas Revesz

http://www.w3.org/2001/XMLSchema#string

Timothy J Counihan

http://www.w3.org/2001/XMLSchema#string

Timothy Lynch

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27

Staging of brain pathology related to sporadic Parkinson's disease

Lewy bodies and parkinsonism in families with parkin mutations

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

Association between early-onset Parkinson's disease and mutations in the parkin gene

Ageing and Parkinson's disease: substantia nigra regional selectivity

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

How much phenotypic variation can be attributed to parkin genotype?

Genetic neuropathology of Parkinson's disease.

P304

571-579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMANEUROL.2013.172

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Andrew John Lees

Laura Silveira Moriyama

John Anthony Hardy

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235787229

http://www.w3.org/2001/XMLSchema#string

P698

23459986

http://www.w3.org/2001/XMLSchema#string

P932

4202385

http://www.w3.org/2001/XMLSchema#string